- Advanced search
- Immuno Portal
- Malaria Portal
florbetaben is an approved drug (EMA & FDA (2014))
Compound class: Synthetic organic
Comment: Florbetaben F18 is the third PET (positron-emission tomography) reagent approved to identify amyloid-β (Aβ) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) . Flutemetamol and florbetapir are the two other PET reagents approved for Aβ detection. These diagnostic tools allow direct and non-invasive in vivo visualisation and quantification of Aβ.
1. Barthel H, Sabri O. (2011)
Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
J Alzheimers Dis, 26 Suppl 3: 117-21. [PMID:21971456]
2. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF. (2009)
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.
J Nucl Med, 50 (11): 1887-94. [PMID:19837759]